Piper Sandler analyst Edward Tenthoff lowered the firm’s price target on Omega Therapeutics (OMGA) to $4 from $9 and keeps an Overweight rating on the shares. The firm cites Omega’s pipeline changes post the Q3 report for the target cut. The company is looking to partner OTX-2002 and deprioritizing OTX-2101 and CXCL1-8, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMGA:
- Omega Therapeutics provides updated MYCHELANGELO I data
- Omega Therapeutics CEO Mahesh Karande to depart, Kaan Certel to succeed
- Omega Therapeutics reports Q3 revenue $2.61M, consensus $1.34M
- Omega Therapeutics Restructures Leadership and Strategic Focus
- Omega Therapeutics Welcomes Robert Rosiello to Board